Navigation Links
Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
Date:2/12/2008

SAN CARLOS, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced a restructuring today designed to complete its transition from a drug delivery service provider to a therapeutics drug development organization. The restructuring will streamline the company, consolidate corporate functions, and strengthen decision-making and execution within the business units.

"We are transforming Nektar into a world-class drug development company and these changes are a natural progression on the path to achieving this vision," said Howard W. Robin, President and Chief Executive Officer of Nektar. "This restructuring aligns the organization with the future direction of our company and strengthens our ability to drive programs rapidly through the clinic."

Approximately 150 positions have been eliminated as a result of the restructuring. Importantly, Nektar has preserved the necessary technical and manufacturing personnel and capabilities to support its ongoing effort to forge a new partnership for its inhaled insulin programs.

Nektar has made significant progress this past year in advancing its proprietary pipeline. The company recently initiated phase 2 clinical trials for its two leading PEGylated small molecule programs, NKTR-102 (PEG-irinotecan) for solid tumors and NKTR-118 (oral PEG-naloxol) for opioid bowel dysfunction. NKTR-061 (inhaled amikacin), which is being co-developed with Bayer AG to treat hospital-acquired pneumonia, is expected to enter Phase 3 trials this year.

The company will release its full financial results for the fourth quarter and full year 2007 on February 27, 2008. At that time, it will host a conference call for investors and analysts beginning at 2:00 PM PT/5:00 PM
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
2. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
3. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
4. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
5. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. PAREXEL International Announces 2-For-1 Stock Split
10. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
11. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 Dr. Sparano is Professor of ... at the Albert Einstein College of Medicine and Associate ... Medical Center. He is also Associate Director for ... the Einstein Breast Cancer Working Group, a multidisciplinary group ... research. He also serves as Vice Chair of the ...
(Date:5/17/2013)... rejection occurs when the transplant recipient,s immune system identifies ... It was previously thought that T cells, the immune ... molecules known as chemokines in order to migrate to ... Journal of Clinical Investigation , Fadi Lakkis and colleagues ... that chemokine stimulation of T cells is not required ...
(Date:5/17/2013)... - Elsevier, a world-leading provider of scientific, technical and ... of a recent study in Reproductive BioMedicine ... that those with an abnormal chromosomal composition can be ... to blastocysts, thereby classifying the risk of genetic abnormality ... group has undertaken a retrospective study, using their predictive ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 •    First of ... Certified for sustainability ,     New facility will help ... , Syngenta unveiled its new crop ... the company’s RTP Innovation Center. The first of its ... to simulate any agricultural climate and precisely measure plant ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3
... NEW HAVEN, Conn., March 17 VION,PHARMACEUTICALS, INC. (Nasdaq: ... quarter and year-end of 2007., The Company reported ... share,for the year ended December 31, 2007, compared with ... for 2006. Weighted-average common shares,outstanding for the years ended ...
... -Abstract describes six-gene biomarker panel for assessment of current risk ... ... 17 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN),a company focused on ... the early detection of diseases and personalized,health management, today announced ...
... March 17 Axial Biotech, Inc., a company,revolutionizing ... motion preserving technologies, announced today that it has ... the first genetic,prognostic test for Adolescent Idiopathic Scoliosis ... its Series B financing. The Series B financing ...
Cached Biology Technology:Vion Reports 2007 Fourth Quarter and Year-End Results 2Vion Reports 2007 Fourth Quarter and Year-End Results 3Vion Reports 2007 Fourth Quarter and Year-End Results 4GeneNews selected to present late-breaking abstract at AACR Annual Meeting 2Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing 2
(Date:5/17/2013)... Scientists investigating the interaction of a group of proteins ... damage have identified a new target that could increase ... the University,s School of Biochemistry and published in the ... Reviews, could eventually lead to new therapies for stroke ... earlier work by the team which identified a protein, ...
(Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
(Date:5/16/2013)... ancient shorelines to predict the stability of today,s largest ice ... from three million years ago, for example when Earth ... be evidence of a high sea level due to ice ... scientists to think that if the world,s largest ice sheets ... same in our modern, progressively warming world. , However, ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2New X-ray method shows how frog embryos could help thwart disease 2World's biggest ice sheets likely more stable than previously believed 2
... study severe weather and climate change joined forces to ... of severe storms in the future and discovered a ... of the United States. The Purdue University-led team ... to formation of severe thunderstorms - those that produce ...
... of Nottingham studies exploring the causes and treatment of ... to the development of drugs to battle these debilitating ... the University has been awarded a total of 1.24m ... has awarded Prof Alan Knox and Dr Linhua Pang ...
... La Jolla, CA Cells cultured in the lab are ... not reflect their biological function within an entire organ or ... a big challenge. One way to get around ... mouse livers with human hepatocytes in the hope of creating ...
Cached Biology News:Research forecasts increased chances for stormy weather 2Research forecasts increased chances for stormy weather 3Research forecasts increased chances for stormy weather 4Research forecasts increased chances for stormy weather 5HATS off to combat asthma 2New chimeric mouse model for human liver diseases, drug testing 2
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB...
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
... Ion Channel Cell Lines ,High Quality, Functionally-Validated, ... are well known for having a critical ... consequently have a key function in pain, ... ion channels have been investigated in therapeutic ...
Biology Products: